A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pheon Therapeutics
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
Kestrel Therapeutics, Inc.
Boehringer Ingelheim
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
IDEAYA Biosciences
Pfizer
Revolution Medicines, Inc.
Stanford University
Conjupro Biotherapeutics, Inc.
DeuterOncology
City of Hope Medical Center
Alterome Therapeutics, Inc.
M.D. Anderson Cancer Center
University Hospital Heidelberg
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
H. Lee Moffitt Cancer Center and Research Institute
Pfizer
Emory University
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
Whitehawk Therapeutics, Inc.
University of Vermont
National Cancer Institute (NCI)
SystImmune Inc.
Pfizer
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Conjupro Biotherapeutics, Inc.
Mayo Clinic
RasCal Therapeutics, Inc.
Pfizer
Fred Hutchinson Cancer Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center